NCT Number: NCT03283358
Person-centered Follow up and Health Promotion Program After Revascularization for Intermittent Claudication
The overall aim of the study is to evaluate a nurse-led intervention (person-centered follow up and health promotion) program in comparison to standard follow up for patients treated with surgical or endovascular revascularization of Intermittent Claudication.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Department of Surgery, Unit of Vascular Surgery, Södersjukhuset, Stockholm, Sweden
About this study
Specific Aims:
- To evaluate the effect of the intervention program on patient's adherence to medication (anticoagulant agents, antiplatelet agents and lipid-lowering agents), risk modification and surgical treatment outcomes
- To investigate the effect of the intervention program on patient reported outcomes
- To investigate the effect of the intervention program on patient reported experiences
- To investigate the long-term effect of the intervention program on mortality, cause of death, occurrence/recurrence of cardiovascular disease up to 10 years after the surgical/endovascular treatment
- To compare patient-reported adherence to medication and patient data registry adherence to medication
Hypothesis: Participants in the Intervention Group have better adherence to prescribed medication and a reduced risk for 10-year predicted coronary heart disease (CHD) compared to participants in the Control Group.
Study population:
Patients with Intermittent Claudication scheduled for revascularization, through open surgery or endovascular method, in Stockholm will be screened for inclusion. After informed consent, the participants will be randomized to either Intervention Group or Control Group. Those participants who couldn't receive revascularization after giving consent will be withdrawn from the study and counted as drop outs. Power analysis has showed a required sample size of 186 participants to detect a statistically significant increase in adherence to medication from 50% to 70% (power 0.80, significance value 0.05, two-sided). Expecting 10% drop-out we plan to recruit 210 participants.
Data collection:
Data on primary and secondary outcomes, serum cholesterol, smoking status, serum carbon monoxide, Hba1c, BMI, waist circumference, physical exercise, diet, alcohol consumption, graft patency, re-intervention, hospitalization during the study year, mortality and patient characteristics/demographics will be collected at baseline and one year after treatment. All data will be registered at a local research data base at Karolinska Institutet. All patient-reported outcomes will be collected using web-based questionnaires linked to the data base.
Data analysis:
Comparisons between the Intervention Group and the Control Group will be made using t-test and ANOVA for repeated-measures or Wilcoxon rank-signed test and Kruskall-Wallis according to the underlying distribution for continuous data, and Fischers Exact test for categorical data. Logistic regression analysis will also be performed to adjust for confounding factors. All analyses will be performed according to the Intention-to-treat principle.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Adult patients who is scheduled for revascularization, through open and/or endovascular surgery for IC diagnosed according to Diagnosis Related Group (DRG) with I70.2 or I739B
Exclusion criteria
- Patients not treated through surgery or revascularization
- Patients diagnosed with dementia
- Patients discharge to a nursery home,
- Patients not accountable for administrating their own medications
- Patients with a survival expectancy less than one year
Treatment and study plan
Primary outcomes
-
Adherence to medication
Time frame: One year after surgical or endovascular treatment for Intermittent Claudication
Adherence to medication (anticoagulant agents, antiplatelet agents and lipid-lowering agents) according to the Swedish Prescribed Drug Registry (PDR). dispensed anticoagulant agents, antiplatelet agents (ATC-register B01A) and lipid-lowering agents (ATC-register C10). Those participants who have fetched both medications for the second refill after treatment will be considered adherent.
Secondary outcomes
-
Risk for 10-year predicted coronary heart disease (CHD)
Time frame: One year after surgical or endovascular treatment for Intermittent Claudication
Changes in risk for CHD within 10-years measured by Framingham Risk Score (FRHS).
Other outcomes
-
Patient reported adherence to medication
Time frame: One year after surgical or endovascular treatment for Intermittent Claudication
Patient-reported adherence to medication (anticoagulant agents, antiplatelet agents and lipid-lowering agents).
-
Generic Health-related Quality of Life (HRQOL)
Time frame: One year after surgical or endovascular treatment for Intermittent Claudication
Patient-reported generic HrQoL measured by EQ-5D
-
Condition specific Health-related Quality of Life (HRQOL)
Time frame: One year after surgical or endovascular treatment for Intermittent Claudication
Patient-reported specific HrQoL measured by VascQol-6
-
Beliefs on medication
Time frame: One year after surgical or endovascular treatment for Intermittent Claudication
Patient-reported beliefs on medication measured by Beliefs about Meicines Questionnaire (BMQ)
-
Self-efficacy
Time frame: One year after surgical or endovascular treatment for Intermittent Claudication
Patient-reported Self-efficacy measured by Swedish Version of the General Self-Efficacy Scale
-
Health literacy
Time frame: One year after surgical or endovascular treatment for Intermittent Claudication
Patient-reported health literacy measured by HLS-EU-Q16 SE
-
Patient-experienced quality of care
Time frame: One year after surgical or endovascular treatment for Intermittent Claudication
Patient-experienced quality of care measured by Quality of Care from Patient's Perspective (Swedish version of QPP)
-
Mortality
Time frame: Ten years after surgical or endovascular treatment for Intermittent Claudication
Data on mortality will be extracted from the National Patient Registry and Stockholm County Council's administrative data (VårdanalysdataLager - VAL).
-
Cardiovascular disease
Time frame: Ten years after surgical or endovascular treatment for Intermittent Claudication
Data on occurrence/reoccurrence of cardiovascular disease with hospitalization will be extracted from the National Patient Registry and Stockholm County Council's administrative data (VårdanalysdataLager - VAL).
Sponsors and collaborators
Lead sponsor
Karolinska Institutet
Other
Registry information
Acronym: FASTIC
Important dates
- Study start
- 2016
- Primary completion
- 2019
- Study completion
- 2020
- First posted
- Sep 14, 2017
- Registry last updated
- Oct 28, 2020
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Using KomPas+ in the Treatment of Patients With Intermittent Claudication
NCT05232474
Arterial Occlusive Diseases, Arteriosclerosis
Nijmegen, Netherlands
View Trial DetailsPain Management and Patient Education for Physical Activity in Intermittent Claudication (PrEPAID)
NCT03204825
Agnosia, Arterial Occlusive Diseases
Glasgow, Strathcylde, United Kingdom
View Trial DetailsEfficacy of Acupuncture for Lumbar Spinal Stenosis
NCT03784729
Bone Diseases, Cardiovascular Diseases
Beijing, China
View Trial DetailsA New Heat Therapy Device for Home-based Leg Heating in Patients With Lower-extremity Peripheral Artery Disease
NCT05335161
Arterial Occlusive Diseases, Arteriosclerosis
West Lafayette, Indiana, United States
View Trial Details